Titleist Asset Management LLC Sells 2,096 Shares of Johnson & Johnson $JNJ

Key Points

• Titleist Asset Management LLC reduced its stake in Johnson & Johnson by 19.0%, selling 2,096 shares, and now holds 8,948 shares worth approximately $1.48 million.
• Despite the stake reduction by Titleist Asset Management, other institutional investors, including Lantz Financial LLC and Apexium Financial LP, increased their positions in Johnson & Johnson during the same quarter.
• Johnson & Johnson recently announced a quarterly dividend of $1.30 per share, representing an annualized dividend yield of 2.9%.

Titleist Asset Management LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 19.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,948 shares of the company's stock after selling 2,096 shares during the quarter. Titleist Asset Management LLC's holdings in Johnson & Johnson were worth $1,484,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Elios Financial Group Inc. boosted its position in shares of Johnson & Johnson by 1.5% during the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock worth $746,000 after purchasing an additional 66 shares in the last quarter. Atlantic Family Wealth LLC grew its holdings in Johnson & Johnson by 4.4% during the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock valued at $266,000 after buying an additional 67 shares during the last quarter. MBA Advisors LLC grew its holdings in Johnson & Johnson by 1.2% during the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after buying an additional 68 shares during the last quarter. Sovereign Financial Group Inc. grew its holdings in Johnson & Johnson by 1.8% during the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after buying an additional 69 shares during the last quarter. Finally, Nabity Jensen Investment Management Inc grew its holdings in Johnson & Johnson by 1.5% during the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock valued at $767,000 after buying an additional 69 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock traded down $1.16 on Wednesday, hitting $176.90. 1,980,755 shares of the stock traded hands, compared to its average volume of 8,939,947. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16. The company has a market capitalization of $426.04 billion, a PE ratio of 18.92, a PEG ratio of 2.26 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company's fifty day moving average is $167.02 and its 200 day moving average is $160.33.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the previous year, the firm posted $2.82 EPS. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's payout ratio is 55.61%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of analyst reports. Wall Street Zen cut Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Bank of America boosted their price target on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Thursday, July 17th. Morgan Stanley boosted their price target on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Finally, Citigroup lifted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a report on Thursday, August 21st. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $176.29.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.